治疗难治的淋巴异常的sirolimus治疗:一个开放标签,单臂,多中心,前性试验
Michio Ozeki1,2, Saori Endo1, Shiho Yasue1
1Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Frontiers in medicine
|February 23, 2024
概括
西洛利斯在治疗难治的淋巴异常 (LAs) 方面表现有前途,超过一半的患者经历了部分放射性反应. 这种治疗可以改善LA患者的症状和生活质量.
科学领域:
- 血管异常 血管异常
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 吸收性淋巴异常 (LAs),包括囊性淋巴形,泛性淋巴异常和戈勒姆-斯托特病,存在重大临床挑战.
- 这些情况可能导致严重的症状和不良的患者预后,需要研究新的治疗策略.
研究的目的:
- 通过前性临床试验,评估西洛斯在患有难以治疗的淋巴异常的患者中的疗效和安全性.
主要方法:
- 进行了一项开放式,单臂,多中心前性试验,涉及11名LA患者.
- 患者每天接受口服西洛,剂量调整以保持低谷度在5-15 ng/mL之间.
- 评估的结果包括放射性反应,性能状况,呼吸功能,内脏损伤,生活质量 (QOL) 和52周的安全性.
主要成果:
- 在52周,54.5%的患者 (6/11) 取得了部分放射性反应;没有观察到完整的反应.
- 在第24周,72.7%的患者 (8/11) 显现了部分反应.
- 常见的不良事件包括口腔炎,形皮肤炎,腹和发烧,但西洛被认为是安全和耐受的.
结论:
- 赛洛斯在患有难以治疗的LAs的患者中表现出降低淋巴组织体积的能力.
- 这些发现表明,西洛斯可能会改善这些疾病患者的临床症状和整体生活质量.
更多相关视频
10:31Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017
7.6K
09:38Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
405
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...